Autres langues SELLAS Life Sciences Group, Inc.

Actions

SLS

US81642T2096

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 09/05/2024			Varia. 5j.	Varia. 1 janv.
1,29 ^USD	+0,78 %		-4,44 %	+21,70 %

01/05	SELLAS Life Sciences Group, Inc. SELLAS Life Sciences Group Inc. annonce des résultats préliminaires positifs de l'étude de phase 2 du SLS009 dans la LAM r/r, avec un taux de réponse de 100 % chez les patients porteurs de la mutation ASXL1 au niveau de dose optimal	CI
29/04	SELLAS Life Sciences Group, Inc. annonce une recommandation positive du comité indépendant de surveillance des données suite à la fin du recrutement de l'étude de phase 3 REGAL	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level	01/05
SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level	01/05
SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study	29/04
SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study	29/04
North American Morning Briefing : Powell Awaited -2-	03/04
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update	28/03
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study	26/03
SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML	26/03
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET	19/03
Sector Update: Health Care Stocks Ease Late Afternoon	15/03
Top Midday Decliners	15/03
Sector Update: Health Care Stocks Softer Friday Afternoon	15/03
Sellas Life Sciences Launches $20 Million Direct Offering, Private Placement -- Shares Fall	15/03
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	15/03
SELLAS Life Sciences Group, Inc. announced a financing transaction	15/03
SELLAS Life Sciences : Material Event - Form 8-K	11/03
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships	08/03
SELLAS Life Sciences Group, Inc. Announces Executive Changes	08/03
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference	01/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues SELLAS Life Sciences Group, Inc.

Actions

SLS

US81642T2096

Autres langues

Filtres